A pharmacological approach in newly established retinal vein occlusion model.

Abstract

The mechanism underlying the effects of anti-vascular endothelial growth factor (VEGF) antibody in retinal vein occlusion (RVO) treatment is poorly understood, partly due to the lack of RVO animal models that mimic clinical pathology. The aims of this study were to establish a suitable RVO model, clarify the pathogenic mechanisms, and evaluate the effects of anti-VEGF antibody in the model. Mouse retinal veins were occluded by laser photocoagulation after rose bengal injection. Reduction of the b/a wave amplitude ratio, retinal nonperfusion, cystoid edema, and hard exudates were observed after occlusion, and expression of RVO-related genes was altered. Administration of anti-VEGF antibody immediately, or 7 days, after occlusion resulted in reduction and increase of the nonperfused area, respectively. We conclude that the present model will be useful for clarification of the pathogenic mechanisms, and that the timing of anti-VEGF antibody administration is important for the successful amelioration of retinal nonperfusion.

• Authors: Shinichiro Fuma, Anri Nishinaka, Yuki Inoue, Kazuhiro Tsuruma, Masamitsu Shimazawa, Mineo Kondo, Hideaki Hara
• Journal: Scientific reports (Sci Rep) Vol. 7 Pg. 43509 (03 02 2017) ISSN: 2045-2322 [Electronic] England
• PMID: 28252108 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Cytokines
• Inflammation Mediators
• Vascular Endothelial Growth Factors

Topics

• Angiogenesis Inhibitors (pharmacology)
• Animals
• Antibodies, Monoclonal (pharmacology)
• Cytokines (genetics, metabolism)
• Disease Models, Animal
• Electroretinography
• Gene Expression Regulation (drug effects)
• Inflammation Mediators (metabolism)
• Male
• Mice
• Papilledema (pathology)
• Regional Blood Flow (drug effects)
• Retinal Hemorrhage (pathology)
• Retinal Vein Occlusion (drug therapy, etiology, metabolism, pathology)
• Vascular Endothelial Growth Factors (antagonists & inhibitors)